Asset: Novel antibacterial and anti-inflammatory recombinant polypeptide
Development Stage: Clinical stage
Indication: Drug-resistant bacteria-induced Hospital-Acquired Pneumonia (HAP)
Key Asset Highlights:
（1）Possesses dual-core pharmacological activities of broad-spectrum antibacterial and potent anti-inflammatory effects, targeting both drug-resistant pathogens and excessive pulmonary inflammatory responses for dual-mechanism treatment.
（2）Exerts robust bactericidal activity against multiple clinically prevalent drug-resistant bacterial strains, effectively eradicating causative pathogens of refractory hospital-acquired pulmonary infections.
（3）Significantly inhibits the release of key pro-inflammatory cytokines in lung tissues, alleviating pulmonary inflammatory injury, reducing exudation, and improving pathological changes of pneumonia.
（4）Demonstrates prominent differentiated advantages over conventional antibiotics, with low propensity to induce bacterial drug resistance, providing a novel therapeutic option for intractable drug-resistant bacterial pneumonia.
（5）Exhibits favorable safety and biocompatibility profiles with no obvious systemic toxic reactions, supporting further clinical exploration and continuous therapeutic application for pulmonary infectious diseases.
（6）Protected by a comprehensive and solid intellectual property portfolio, ensuring exclusive and stable global development and commercialization rights for drug-resistant bacterial infection indications.
If you are a Search & Evaluation professional working at an MNC, biopharma, biotech or VC, and are interested in this opportunity, please feel free to contact the DrugTimes BD Team.
Email: BD@drugtimes.cn
Thank you very much!
【Disclaimer】All information presented above and on this website is provided for informational purposes only. We make no guarantee as to its accuracy, completeness or timeliness. Readers shall exercise caution when referencing the content.
发布者：DrugTimes001，转载请首先联系contact@drugtimes.cn获得授权
为好文打赏 支持药时代 共创新未来！ 
